Neurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to induce neurological changes and confer symptom relief. With sections on both natural and synthetic compounds, the book's broad coverage allows readers to learn about their use with multiple conditions, as well as the working biology of the endocannabinoid system, its receptors and its ligands. This volume provides a platform for research on the effects of this system and its modulation in brain function and neurological dysfunction.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Dedication - p. iii 7. Contributors - p. xix 8. Preface - p. xxv 9. Part I: Setting the scene and introductory chapters - p. xxvi 10. Chapter 1. Distribution of the endocannabinoid system: Linking signaling and development - p. 3 11. Chapter 2. The endocannabinoid system, immunomodulation, and LPS-induced inflammation - p. 21 12. Chapter 3. Physiology of the endocannabinoid system: Imaging and the use of positron emission tomography (PET) - p. 39 13. Chapter 4. The endocannabinoid system and aging - p. 53 14. Chapter 5. The endocannabinoid system and posttraumatic stress disorder (PTSD): A new narrative - p. 67 15. Part II: Neurobiology of the endocannabinoid system - p. 79 16. Chapter 6. The protective effect of the endocannabinoid system in neurotoxin-induced damage to hippocampal neurons: a focus on light and electron microscopy - p. 83 17. Chapter 7. Endocannabinoid signaling at excitatory and inhibitory synapses - p. 97 18. Chapter 8. The endocannabinoids and potassium channels—An updated narrative - p. 107 19. Chapter 9. Insights into the endocannabinoid system from investigations of the development of social behavior in rodents of both sexes - p. 123 20. Chapter 10. Exercise and Parkinson’s disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors - p. 137 21. Chapter 11. Endocannabinoids and inhalant misuse: Neuropsychological aspects - p. 149 22. Chapter 12. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disorders - p. 161 23. Chapter 13. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: Interlinking the endocannabinoid system - p. 175 24. Chapter 14. WWL70 targets the link between 2-arachidonoylglycerol and prostanoid pathways - p. 192 25. Chapter 15. Endocannabinoid catabolic enzyme inhibitors and pain alleviation - p. 203 26. Chapter 16. The endocannabinoid system in health and disease: Features in epilepsy - p. 215 27. Chapter 17. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis - p. 229 28. Chapter 18. Endocannabinoid signaling in the lateral habenula regulates opioid addiction - p. 241 29. Chapter 19. On the interplay among endocannabinoid, noradrenergic, and glucocorticoid systems: Evidence from aversive memory studies - p. 259 30. Part III: Receptor biology and responses - p. 267 31. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation - p. 276 32. Chapter 21. Role of hippocampal CB1 and CB2 receptors in fear memory consolidation, extinction, and reconsolidation - p. 285 33. Chapter 22. Possible use of beta-caryophyllene as an agent to facilitate the recovery from COVID-19-induced tissue and organ damage - p. 300 34. Chapter 23. CB1 agonism on mesolimbic and nigrostriatal dopaminergic neurotransmission - p. 309 35. Chapter 24. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes - p. 321 36. Chapter 25. Plasma membrane localization of endocannabinoids system receptors - p. 331 37. Chapter 26. Applications to wound healing: Cannabinoid receptor 1 antagonism and collagen deposition - p. 341 38. Chapter 27. The role of transient receptor potential vanilloid 1 (TRPV1), a modulator of the endocannabinoid system in anxiety, depression, and cocaine addiction - p. 351 39. Chapter 28. Org27569, the allosteric modulators and the cannabinoid receptor 1 (CB1) - p. 365 40. Naturally occurring delta-9-tetrahydrocannabinol derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid system - p. 379 41. Part IV: Profiles and behavior of selective endocannabinoids - p. 394 42. Chapter 30. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system: A chemical approach - p. 403 43. Chapter 31. Fatty acid amide hydrolase, anandamide, and neurological diseases - p. 417 44. Chapter 32. The endocannabinoid system in the immunobiology of dendritic cells - p. 429 45. Chapter 33. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: Linking in the endocannabinoid system - p. 437 46. Chapter 34. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamus - p. 449 47. Chapter 35. Key role of the endocannabinoid system with special emphasis in anandamide on the modulation of cardio-renal homeostasis - p. 461 48. Chapter 36. The endocannabinoid system: Signaling and social motivation - p. 469 49. Part V: Exogenous, synthetic other compounds linking in the endocannabinoid system - p. 478 50. Safety and toxicology of the dietary cannabinoid β-caryophyllene - p. 482 51. Chapter 38. Synthetic cannabinoid receptor agonists: An overview - p. 493 52. Part VI: Comparative studies in nonneurological systems - p. 504 53. Chapter 39. Nonneurological aspects of the endocannabinoid system: Nonalcoholic fatty liver disease - p. 507 54. Chapter 40. Components of the endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAs - p. 519 55. Tumor growth and the endocannabinoid system: Investigating CB2 agonists - p. 532 56. Chapter 42. Linking endocannabinoid system, palmitoylethanolamide, and sarcopenia in view of therapeutic implications - p. 543 57. Part VII: Resources - p. 555 58. Chapter 43. Recommended resources for studying and investigating the neurobiology and physiology of the endocannabinoid system - p. 561 59. Index - p. 567
Neurobiology and Physiology of the Endocannabinoid System offers readers a comprehensive reference on the neurobiology of this system and the use of cannabimimetic compounds to induce neurological changes and confer symptom relief. With sections on both natural and synthetic compounds, the book's broad coverage allows readers to learn about their use with multiple conditions, as well as the working biology of the endocannabinoid system, its receptors and its ligands. This volume provides a platform for research on the effects of this system and its modulation in brain function and neurological dysfunction.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Dedication - p. iii 7. Contributors - p. xix 8. Preface - p. xxv 9. Part I: Setting the scene and introductory chapters - p. xxvi 10. Chapter 1. Distribution of the endocannabinoid system: Linking signaling and development - p. 3 11. Chapter 2. The endocannabinoid system, immunomodulation, and LPS-induced inflammation - p. 21 12. Chapter 3. Physiology of the endocannabinoid system: Imaging and the use of positron emission tomography (PET) - p. 39 13. Chapter 4. The endocannabinoid system and aging - p. 53 14. Chapter 5. The endocannabinoid system and posttraumatic stress disorder (PTSD): A new narrative - p. 67 15. Part II: Neurobiology of the endocannabinoid system - p. 79 16. Chapter 6. The protective effect of the endocannabinoid system in neurotoxin-induced damage to hippocampal neurons: a focus on light and electron microscopy - p. 83 17. Chapter 7. Endocannabinoid signaling at excitatory and inhibitory synapses - p. 97 18. Chapter 8. The endocannabinoids and potassium channels—An updated narrative - p. 107 19. Chapter 9. Insights into the endocannabinoid system from investigations of the development of social behavior in rodents of both sexes - p. 123 20. Chapter 10. Exercise and Parkinson’s disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors - p. 137 21. Chapter 11. Endocannabinoids and inhalant misuse: Neuropsychological aspects - p. 149 22. Chapter 12. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disorders - p. 161 23. Chapter 13. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: Interlinking the endocannabinoid system - p. 175 24. Chapter 14. WWL70 targets the link between 2-arachidonoylglycerol and prostanoid pathways - p. 192 25. Chapter 15. Endocannabinoid catabolic enzyme inhibitors and pain alleviation - p. 203 26. Chapter 16. The endocannabinoid system in health and disease: Features in epilepsy - p. 215 27. Chapter 17. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis - p. 229 28. Chapter 18. Endocannabinoid signaling in the lateral habenula regulates opioid addiction - p. 241 29. Chapter 19. On the interplay among endocannabinoid, noradrenergic, and glucocorticoid systems: Evidence from aversive memory studies - p. 259 30. Part III: Receptor biology and responses - p. 267 31. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation - p. 276 32. Chapter 21. Role of hippocampal CB1 and CB2 receptors in fear memory consolidation, extinction, and reconsolidation - p. 285 33. Chapter 22. Possible use of beta-caryophyllene as an agent to facilitate the recovery from COVID-19-induced tissue and organ damage - p. 300 34. Chapter 23. CB1 agonism on mesolimbic and nigrostriatal dopaminergic neurotransmission - p. 309 35. Chapter 24. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes - p. 321 36. Chapter 25. Plasma membrane localization of endocannabinoids system receptors - p. 331 37. Chapter 26. Applications to wound healing: Cannabinoid receptor 1 antagonism and collagen deposition - p. 341 38. Chapter 27. The role of transient receptor potential vanilloid 1 (TRPV1), a modulator of the endocannabinoid system in anxiety, depression, and cocaine addiction - p. 351 39. Chapter 28. Org27569, the allosteric modulators and the cannabinoid receptor 1 (CB1) - p. 365 40. Naturally occurring delta-9-tetrahydrocannabinol derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid system - p. 379 41. Part IV: Profiles and behavior of selective endocannabinoids - p. 394 42. Chapter 30. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system: A chemical approach - p. 403 43. Chapter 31. Fatty acid amide hydrolase, anandamide, and neurological diseases - p. 417 44. Chapter 32. The endocannabinoid system in the immunobiology of dendritic cells - p. 429 45. Chapter 33. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: Linking in the endocannabinoid system - p. 437 46. Chapter 34. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamus - p. 449 47. Chapter 35. Key role of the endocannabinoid system with special emphasis in anandamide on the modulation of cardio-renal homeostasis - p. 461 48. Chapter 36. The endocannabinoid system: Signaling and social motivation - p. 469 49. Part V: Exogenous, synthetic other compounds linking in the endocannabinoid system - p. 478 50. Safety and toxicology of the dietary cannabinoid β-caryophyllene - p. 482 51. Chapter 38. Synthetic cannabinoid receptor agonists: An overview - p. 493 52. Part VI: Comparative studies in nonneurological systems - p. 504 53. Chapter 39. Nonneurological aspects of the endocannabinoid system: Nonalcoholic fatty liver disease - p. 507 54. Chapter 40. Components of the endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAs - p. 519 55. Tumor growth and the endocannabinoid system: Investigating CB2 agonists - p. 532 56. Chapter 42. Linking endocannabinoid system, palmitoylethanolamide, and sarcopenia in view of therapeutic implications - p. 543 57. Part VII: Resources - p. 555 58. Chapter 43. Recommended resources for studying and investigating the neurobiology and physiology of the endocannabinoid system - p. 561 59. Index - p. 567
